Elite Pharmaceuticals reported a standout QQ4 2024 performance anchored by the transition to an Elite label-driven model and a rapidly expanding ANDA pipeline. For the year ended March 31, 2024, total revenues reached $56.6 million, up 65% year over year from $34.2 million, reflecting the monetization of previously licensed products as Elite brought more activities in-house. Operating income surged to approximately $10.8 million, a 192% YoY increase, as higher revenue dollars and improved margins accompanied the substantial upfront investments required to support an in-house marketing and distribution framework. The business generated a one-time, noncash tax benefit of about $19.6 million related to deferred tax assets (NOLs) that released reserves, contributing to net income materially above operating income. Net income for the period benefited from this tax treatment, helping drive a reported top-line improvement beyond operating performance. Balance sheet metrics improved markedly: working capital effectively doubled to roughly $28 million, equity more than doubled to about $57.6 million, and debt remained low at roughly $11.7 million with net debt around $4.6 million. The company added four approved ANDAs after March 31, including methotrexate, and executed a strategic shift toward direct Elite label sales, supported by a new packaging line and a 34,000 square foot facility expansion. Management projects continued growth through four additional FDA-reviewed ANDAs and a target to achieve a minimum of $70 million in revenue for the fiscal year ending March 2025, signaling a constructive multi-year trajectory. The quarter also featured management emphasis on risk management (regulatory, pricing, and DEA quota considerations) and an ongoing focus on capital-efficient growth, with a pipeline designed to sustain profitability as scale accelerates.